Biotech Startups
9,979 companies tagged Biotech, with their investors and founders.
WSG describes itself as an investment or holding company focused on growth in the life sciences and microelectronics fields, with stated interest in the semiconductor, AI infrastructure, and biotechnology sectors. The page addresses shareholders and describes the company's strategy of scaling businesses in these high-growth areas.
2 investors
Surginex develops lipid nanoparticle and RNA platforms for therapeutic applications, serving pharmaceutical and biotech companies in drug development.
2 investors
APITbio develops antibody-based therapeutics using a proprietary fully human antibody library, with platforms for antibody discovery, engineering, optimization, production, and bispecific antibody creation. Its pipeline includes monoclonal antibodies, bispecific antibodies, and a CAR-T program under joint research.
2 investors
AccuRna develops drug delivery systems for nucleic acid therapeutics, including antisense oligonucleotides, siRNA, miRNA, and mRNA-based treatments. The company focuses on enabling the development of novel medicines for refractory diseases with no current cure.
2 investors
Ac-Planta develops and manufactures biostimulant products that enhance plants' tolerance to drought, high temperature, and salt stress, along with agricultural and horticultural materials for farms and plant factories. The company applies epigenetics and acetic acid-based biotechnology to address food security and environmental challenges caused by climate change.
2 investors
IMMUNOSENS manufactures in vitro diagnostic pharmaceuticals and third-class medical devices for clinical diagnostic purposes. The company holds regulatory approvals from Japanese authorities for these medical products.
2 investors
Orizuru Therapeutics develops cellular therapy products and regenerative medicine treatments utilizing iPS cell-related technology. The company supports drug discovery research and establishes regenerative medicine research infrastructure for the Japanese healthcare and biotechnology sectors.
2 investors
Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
2 investors
Kringle Pharma develops and manufactures HGF protein-based pharmaceuticals for treating conditions including spinal cord injury, ALS, and vocal cord scarring. The company is a spin-out of Osaka University and Keio University focused on drug development in the biotech sector.
2 investors
Solasia is a pharmaceutical company that in-licenses promising drug candidates from overseas and domestic pharma and biotech companies and develops them through clinical trials for the Japanese and Asian markets. Founded in 2006, it focuses on supplying cancer-related medicines to patients across Japan and other Asian countries.
2 investors
Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection. It initially targets patients with congenital tooth agenesis (a rare genetic condition) and ultimately aims to treat tooth loss from decay or periodontal disease.
2 investors
Hynts Technology develops nanotechnology-based products for cellular delivery and extraction applications. The company offers nanostructured membrane stamps, microscope-mounted stamping systems, and cell processing services for research and biotech applications.
2 investors
FIMECS, Inc. is a Japanese drug discovery company researching and developing new pharmaceuticals based on targeted protein degradation mechanisms.
2 investors
BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
2 investors
PtBio develops genome editing technology and bio-DX tools for analyzing the genomes of industrially used organisms, positioning itself as a platform provider. Its applications include allergy-free eggs, CO2-converting microalgae for carbon recycling, advanced medical treatments, resource-recycling agriculture, aquatic resource supply, and bio-manufacturing.
2 investors
XtalPi is an AI-driven materials discovery platform that combines computational chemistry, machine learning, and automated wet lab experimentation to accelerate research in pharmaceuticals, new materials, and clean energy. The company serves biotech, pharmaceutical, and materials science organizations globally.
2 investors
EXORPHIA develops extracellular vesicle (EV) technology for assisted reproductive medicine, focusing on cell-free IVF culture medium additives to improve embryo development and fertilization success rates. The company targets fertility clinics and academic institutions in reproductive medicine.
2 investors
iXgene develops regenerative medicine therapies using genome-edited induced pluripotent stem cells (iPSCs) to treat conditions including glioblastoma and traumatic brain injury. The company focuses on gene and cell therapies derived from genetically engineered stem cells.
2 investors
Mitate Zepto Technica develops specialized semiconductor and computing hardware for genome analysis, including custom processors, accelerator boards, and supercomputers that perform genomic sequencing at significantly higher speeds and lower costs than conventional systems.
2 investors
Chiome is a Japanese biotech venture that discovers and develops antibody drugs targeting unmet medical needs. It works to create drug candidates and build product pipelines through collaboration with external institutions.
2 investors
Kino Pharma is a Japan-based company with a Tokyo headquarters and a Kyoto research laboratory. The page provides only corporate location information and does not describe the company's products or services.
2 investors
TWOCELLS (株式会社ツーセル) is a regenerative medicine venture developing therapies and products based on mesenchymal stem cells (MSCs), including its gMSC series for cartilage regeneration, along with serum-free culture media (STK series) and consulting services. Founded as a Hiroshima University spin-off, it also licenses its technology to pharmaceutical partners.
2 investors
Kabushiki Kaisha PhoenixBio is a Japanese biotechnology company established in 2002. It operates subsidiaries in the United States, including PhoenixBio USA Corporation and CMHL Consortium LLC.
2 investors
MedRx is a Japanese pharmaceutical company developing new drugs based on transdermal delivery technologies such as its ILTS and NCTS platforms and microneedle arrays. It is a publicly listed company focused on creating novel therapeutics for patients with various diseases.
2 investors